Home » Stocks » CNTA

Centessa Pharmaceuticals Limited (CNTA)

Stock Price: $20.64 USD -0.43 (-2.04%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 1.80B
Revenue (ttm) n/a
Net Income (ttm) -51.58M
Shares Out 87.42M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $20.64
Previous Close $21.07
Change ($) -0.43
Change (%) -2.04%
Day's Open 20.88
Day's Range 20.26 - 21.15
Day's Volume 90,594
52-Week Range 19.61 - 26.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

If two heads are better than one, consider what 10 can accomplish. That's the thinking behind Centessa Pharmaceuticals ( CNTA , Financial), a company constructed from the merger of 10 small drug companies.

1 month ago - GuruFocus

If two heads are better than one, consider what ten can accomplish.

1 month ago - GuruFocus

CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, deve...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Centessa Announces Pricing of Initial Public Offering

2 months ago - Business Wire

Centessa Pharmaceuticals, with four clinical and a dozen preclinical programs, expects its initial public offering to be slightly over the $250 million raised in a January series A. The largest single r...

2 months ago - FierceBiotech

Centessa Pharmaceuticals Limited has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About CNTA

Centessa Pharmaceuticals was conceived by combining the primary strengths of the asset-centric model with the benefits of diversification and scale typically attributed to traditional large R&D organizations. The asset-centric model refers to single-purpose companies which are focused on developing a single program or programs associated with a single biological pathway. We have implemented this reimagined approach to R&D by initially combining a curated portfolio of ten wholly-owned asset-centric companies, which we refer to as the Centessa Su... [Read more...]

Industry
Biotechnology
IPO Date
May 28, 2021
CEO
Saurabh Saha, M.D., Ph.D.
Employees
34
Stock Exchange
NASDAQ
Ticker Symbol
CNTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for CNTA is 38.00, which is an increase of 84.11% from the latest price.

Price Target
$38.00
(84.11% upside)